| Name | Title | Contact Details |
|---|---|---|
Alex Lagares |
VP of Growth | Profile |
Ledgebrook is an InsurTech MGA on a mission to bring Specialty insurance into the modern era. Burdened with legacy technology and processes, the industry has not kept pace with the speed of innovation seen in other sectors. Positioned at the cutting edge of the next generation of InsurTech, Ledgebrook offers the best of both worlds: innovative world-class technology deployed by a leadership team armed with decades of insurance expertise. Our long-term vision is to become a diversified full stack Specialty re/insurer competing with legacy carriers in product lines & markets across the globe. To get there Ledgebrook will build our premium base by rolling out a new Specialty product every ~6 months until we prove enough traction to raise a balance sheet, become a full stack carrier and eventually compete in the reinsurance markets as well. Our initial product will be domestic primary and excess GL E&S policies sourced via wholesale brokers. At Ledgebrook everything we do is driven by our culture: Care, Strive, Thrive Together. To succeed in modernizing the industry, we must first succeed in changing the way we do business. Talent density is our north star—fewer, better people working together as one. To that end weve replaced all individual incentives with generous equity packages—we play as a team, we win as a team. Everyone benefits handsomely from Ledgebrooks success. Ledgebrook is a fully-remote US based company backed by top venture investors including Brand Foundry & American Family Ventures.
With so much conflicting and confusing information surrounding Medicare, its easy to feel unsure about how to choose the best plan(s). At MedicareSchool.com, we empower you with the knowledge and guidance you need to get the best Medicare plans and live retirement worry-free.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Herspiegel is a consulting firm based in Pennsylvania, founded in 2007, that specializes in pharmaceutical and biotech commercialization services. With over fifteen years of experience, the company has supported more than 150 product launches across various therapeutic areas, including primary care, oncology, and rare diseases. Their mission is to create a model for successful pharmaceutical product launches. The firm offers a wide range of services tailored to the life sciences industry, including market access, medical affairs, marketing strategy, and operational execution. Herspiegels team consists of over 350 experts, including MDs, PhDs, MBAs, and pharmacists, who provide deep knowledge to help clients navigate complex challenges and maximize brand potential. They serve a diverse clientele, from startups to large global pharmaceutical companies, focusing on strategic insights and operational excellence to enhance commercial success and patient outcomes. Herspiegel has also expanded its capabilities through strategic acquisitions, such as Decisive Consulting, which enhances their market access and value strategy services. This positions Herspiegel to deliver innovative solutions in a dynamic pharmaceutical landscape.